Business Segment Information (Tables)

6 Months Ended

Apr. 30, 2026

Segment information:


Periods Ended April 30,	Three Months				Six Months
(In millions)	2026		2025		2026		2025
CooperVision net sales by category:
Toric and multifocal	$	364.9	$	328.4	$	716.1	$	647.8
Sphere, other	358.6		341.2		702.5		667.9
Total CooperVision net sales	$	723.5	$	669.6	$	1,418.6	$	1,315.7
CooperSurgical net sales by category:
Office and surgical	$	214.2	$	205.8	$	416.6	$	404.7
Fertility	143.8		126.9		270.4		246.6
Total CooperSurgical net sales	358.0		332.7		687.0		651.3
Total net sales	$	1,081.5	$	1,002.3	$	2,105.6	$	1,967.0


(In millions)	CooperVision		CooperSurgical		Corporate (1)		Consolidated
Three Months Ended April 30, 2026
Net sales	$	723.5	$	358.0	$	—	$	1,081.5
Cost of sales	229.4		116.7		—		346.1
Selling, general and administrative expense	252.2		402.4		21.6		676.2
Research and development expense	22.1		20.4		—		42.5
Amortization expense	4.2		43.5		—		47.7
Operating income (loss)	$	215.6	$	(225.0)	$	(21.6)	$	(31.0)
Interest expense							20.9
Other (income) expense, net							(3.5)
Income (loss) before income taxes							$	(48.4)
Depreciation expense	$	41.3	$	6.5	$	—	$	47.8
Capital expenditures	$	76.6	$	9.8	$	—	$	86.4
As of April 30, 2026
Identifiable assets	$	7,626.0	$	4,616.0	$	240.3	$	12,482.3
Three Months Ended April 30, 2025
Net sales	$	669.6	$	332.7	$	—	$	1,002.3
Cost of sales	215.6		107.6		—		323.2
Selling, general and administrative expense	236.9		136.8		25.3		399.0
Research and development expense	25.6		19.9		—		45.5
Amortization expense	5.1		44.7		—		49.8
Operating income (loss)	$	186.4	$	23.7	$	(25.3)	$	184.8
Interest expense							24.2
Other (income) expense, net							16.1
Income (loss) before income taxes							$	144.5
Depreciation expense	$	37.1	$	5.9	$	—	$	43.0
Capital expenditures	$	69.4	$	8.7	$	—	$	78.1
As of October 31, 2025
Identifiable assets	$	7,604.4	$	4,619.3	$	171.1	$	12,394.8

(1) Corporate SGA expenses are not allocated to the segments.


(In millions)	CooperVision		CooperSurgical		Corporate (1)		Consolidated
Six Months Ended April 30, 2026
Net sales	$	1,418.6	$	687.0	$	—	$	2,105.6
Cost of sales	450.2		224.8				675.0
Selling, general and administrative expense	489.8		530.8		45.8		1,066.4
Research and development expense	44.5		42.3				86.8
Amortization expense	8.3		87.3				95.6
Operating income (loss)	$	425.8	$	(198.2)	$	(45.8)	$	181.8
Interest expense							43.3
Other (income) expense, net							(5.3)
Income (loss) before income taxes							$	143.8
Depreciation expense	$	82.4	$	13.0	$	—	$	95.4
Capital expenditures	$	170.8	$	17.8	$	—	$	188.6
Six Months Ended April 30, 2025
Net sales	$	1,315.7	$	651.3	$	—	$	1,967.0
Cost of sales	420.6		207.1		—		627.7
Selling, general and administrative expense	466.8		272.7		47.4		786.9
Research and development expense	48.1		38.1		—		86.2
Amortization expense	9.9		89.5		—		99.4
Operating income (loss)	$	370.3	$	43.9	$	(47.4)	$	366.8
Interest expense							50.2
Other (income) expense, net							18.8
Income (loss) before income taxes							$	297.8
Depreciation expense	$	72.4	$	12.0	$	—	$	84.4
Capital expenditures	$	145.0	$	22.5	$	—	$	167.5

(1) Corporate SGA expenses are not allocated to the segments.

Geographic information:


Periods Ended April 30,	Three Months				Six Months
(In millions)	2026		2025		2026		2025
Net sales to unaffiliated customers by country of domicile:
United States	$	547.8	$	515.2	$	1,061.7	$	1,011.6
Europe	341.6		291.9		668.0		579.4
Rest of world	192.1		195.2		375.9		376.0
Total	$	1,081.5	$	1,002.3	$	2,105.6	$	1,967.0


(In millions)	April 30, 2026		October 31, 2025
Net property, plant and equipment by country of domicile:
United States	$	1,429.1	$	1,389.4
Europe	445.7		429.1
Rest of world	257.4		263.5
Total	$	2,132.2	$	2,082.0